恒瑞医药子公司HRS9531注射液上市许可申请获受理

Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration (NMPA) for the drug listing application of HRS9531 injection [1] Group 1 - The drug HRS9531 is intended for long-term weight management in adults with a body mass index (BMI) of ≥28 kg/m² (obesity) or ≥24 kg/m² (overweight) with at least one weight-related comorbidity, such as high blood sugar, hypertension, dyslipidemia, obstructive sleep apnea, or fatty liver [1]